TRENTON, NJ (MERCER)–Around 9:15 pm tonight Trenton Police responded to the shopping center in the 200 Block of North Hermitage Avenue for shots fired. There were numerous 9-1-1 calls reporting the shooting and estimated to be around 25 rounds. The victim was transported by personal vehicle to the Trauma Center at Capital Health Regional Medical Center. No further information is available.
At 11:47 pm Trenton Police again were sent to the first block of West Greenway Walkway for a stabbing. Trenton Fire Department, Trenton EMS and Capital Health Paramedics responded. A “trauma alert” was called at 11:54 pm as the ambulance transported to the Trauma Center at Capital Health Regional Medical Center
This is a Breaking News Report from radio, witnesses and/or on scene reporting. Usually in the City of Trenton no information is released on crimes and shootings unless it is a fatal and comes though the Mercer County Prosecutor’s Office. If official information is released and available the story will be updated with current information and any corrections made.
CAMDEN, NJ –A New Jersey doctor was charged in connection with his role in a longstanding billing fraud scheme, U.S. Attorney Craig Carpenito announced today.
Morris Antebi, 68, of Long Branch, New Jersey, is charged by complaint with three counts of health care fraud, wire fraud, and mail fraud for his role in the scheme. Antebi is scheduled to appear today by videoconference before U.S. Magistrate Judge Joel Schneider.
According to documents filed in this case and statements made in court:
Antebi, a physician specializing in pain management and anesthesia, owned and operated a pain management clinic chain with locations throughout South Jersey. Antebi was a participating provider in Medicare, Medicaid, and several private insurance plans. Between approximately 2014 through 2020, Antebi billed over $24.6 million for services he purportedly provided, including billing more than $15.3 million to Medicaid and more than $8 million to Medicare.
The investigation showed that Antebi engaged in various forms of billing fraud. For example, Antebi frequently billed Medicare, Medicaid, and private insurance companies on dates when travel records show he was overseas, including on trips to China, Israel, Turkey, the Dominican Republic, and across Europe, or when he was otherwise outside the State of New Jersey. Antebi billed approximately $230,700 to Medicaid, Medicare, and private insurance plans between November 2015 and January 2020 for services he purportedly rendered while he was traveling and not in the office.
The investigation also showed that Antebi billed for excessive billings for one-day periods of time. For example, Antebi billed insurance plans for more than 24 hours’ worth of services in a one-day period of time on more than 900 occasions between 2014 and 2020. Antebi also billed insurance companies for between 12 and 23.99 hours of purported services in a one-day period of time on more than 300 occasions. On certain occasions, law enforcement surveilled Antebi on days when he left the clinics early, but nevertheless billed as though he saw many patients on those days.
Despite these high billings, individuals interviewed during the investigation stated that Antebi commonly saw them for only very brief periods of time, and he often did not perform any medical exams or evaluations during their visits. Individuals also indicated that that there sometimes was no medical equipment or examination tables in the rooms at the clinics in which patients met with providers, and that patients sometimes met with providers on folding chairs in the hallway of the clinics.
The health care fraud count carries a maximum penalty of 10 years in prison and a $250,000 fine, or twice the gross gain or loss from the offense. The wire fraud and mail fraud counts each carry a maximum penalty of 20 years in prison and a $250,000 fine, or twice the gross gain or loss from the offense.
U.S. Attorney Carpenito credited agents of the FBI’s Atlantic City Resident Agency Health Care Fraud Task Force, under the direction of Special Agent in Charge George M. Crouch Jr. in Newark; the U.S. Department of Health and Human Services – Office of Inspector General, under the direction of Special Agent in Charge Scott J. Lampert, the U.S. Department of Labor – Office of Inspector General, New York Region, under the direction of Special Agent in Charge Michael C. Mikulka, the U.S. Drug Enforcement Administration, under the direction of Special Agent in Charge Susan A. Gibson in Newark, and IRS-Criminal Investigation, under the direction of Special Agent in Charge Michael Montanez in Newark with the investigation leading to the criminal complaint and officers of the Northfield Police Department. U.S. Attorney Carpenito also credited agents of FBI’s Headquarters Health Care Fraud Unit Data Analysis Response Team under the direction of Special Agent Greg Heeb in Washington, D.C.
The government is represented by Assistant U.S. Attorneys Christina O. Hud and Daniel A. Friedman of the U.S. Attorney’s Office in Camden.
The charges and allegations contained in the complaint are merely accusations, and the defendant is presumed innocent unless and until proven guilty.
New Jersey Transit Police help save commuter’s life. NJTPD Officers at Trenton Station responded to reports of a commuter that had fallen between the train and raised platform. Observing substantial bleeding and an immediate need for assistance, the officers quickly worked together to render aid.
Officer Peter Jackson applied a tourniquet to address the life-threatening loss of blood. Additional officers provided gauze to dress the wound and administered oxygen. With the subject stabilized, the officers kept the commuter alert until EMS arrival.
These officers used their training, equipment, and solid teamwork to render aid during a life-threatening situation. If someone you know was suffering from a life-threatening bleed and had minutes to live, would you know what to do? Please take a minute to view the NJTPD Training Unit video and learn how to make or apply a tourniquet at police.njtransit.com/bleed.
Great work by NJTPD District 5 Officers Paul Fevola, Kenneth Podolski, Michael Virag, Carmine Ruocco, (not pictured: Sgt. Jason Conrad and Peter Jackson.)
November 9, 2020 11:53 am with additional update at 6:45 pm with additional details.
November 9, 2020 6:45 pm update:
Trooper Charles Marchan of the NJ State Police Public Information Bureau told MidJersey.News tonight, that Based on preliminary investigation, Emily C. Dengler was operating a Honda Accord westbound on Stagecoach Road CR 524. William F. Morelli, was operating a Harley Davidson eastbound on Stagecoach Road CR 524 with Laura Zylinski as a rear passenger. The Honda ran off the road, struck a mailbox and re-entered the roadway colliding with the front of the Harley. Both occupants of the motorcycle were ejected.
William Morelli, 56, from Wall, NJ was pronounced at 1:48 p.m.
November 9, 2020 11:53 am update:
MILLSTONE TOWNSHIP, NJ (MONMOUTH)–NJ State Police Sgt. Lawrence Peele of the Public Information Bureau told MidJersey.News that the driver of the motorcycle in yesterday’s crash, William Morelli, 56, of Wall, N.J., died as a result of injuries sustained in the crash at Centra State Hospital. The passenger remains in serious condition at Jersey Shore Medical Center.
3:30 pm update: Trooper II Alejandro Goez, from the NJ State Police Public Information Bureau told MidJersey.News that an accident was reported at 12:33 pm in the area of 125 Stagecoach Road in Millstone Twp. involving a car and a motorcycle.
There were no reported injuries to the driver of the car. The driver and occupant of the motorcycle sustained serious injuries. One was airlifted to Jersey Shore Medical and the other was taken via ambulance to Centra State Hospital.
The road is currently shutdown for the accident investigation.
Earlier MidJersey.News story here:
MILLSTONE TOWNSHIP, NJ (MONMOUTH)–Around 12:30 pm a serious accident occurred, in the 100 Block of Stagecoach Road (CR 524) between Stillhouse Road and Charleston Spring Road. Millstone Township Fire Department, RWJ EMS, paramedics, NJSP and two helicopters were sent to the scene.
Not much is known about the accident but one person was transported to Jersey Shore Medical Center by Hackensack Meridian Health helicopter and another person was transported to CentraState Medical Center by ground.
Expect the roadway to be closed until the accident investigation is completed by the NJSP Serious Accident Investigation Unit.
EAST WINDSOR, NJ (MERCER)–East Windsor Police reported that on Saturday, November 7, 2020 at approximately 3:47 P.M. East Windsor Police responded to a reported motor vehicle crash on Rt. 130 North involving three motor vehicles.
Preliminary investigation revealed the operator of a 2008 Nissan Sentra driven by Sylvester Massaro, 83 of East Windsor entered Rt. 130 North after exiting the parking lot of the American Legion when it collided with a 2012 Honda Accord driven by Rajdeep Sekhon, 32 of Bordentown, which was traveling north on Rt. 130. The Honda Accord left the roadway and collided with a 2004 Econovan, which was legally parked and unoccupied.
Sylvester Massaro, 83 of East Windsor sustained non-life threatening injuries as a result of the collision and she was transported to Capital Health Regional in Trenton, NJ by Rescue Squad personnel.
Rajdeep Sekhon, 32 of Bordentown sustained life threatening injuries as a result of the collision and he was transported to Capital Health Regional in Trenton, NJ by Rescue Squad personnel.
The matter remains under investigation by the East Windsor Police Department’s Traffic Safety Unit and the Mercer County Prosecutor’s Office Serious Collision Response Team. No charges have been filed at this time.
Responding agencies are: East Windsor Police Department, Highstown Police Department, Robbinsville Police Department, Mercer County Prosecutor’s Office, East Windsor Rescue Squad Districts 1 & 2, East Windsor Fire Company Station 42, Hightstown Fire Company Station 41 and the NJ State DOT Incident Management Team.
Today Albert Bourla Chief Executive Officer of Pfizer (with several locations in NJ- and executive aircraft hanger at Trenton-Mercer County Airport in Ewing) has announced in a letter and press release that their COVID-19 vaccine candidate was found to be more than 90% effective in preventing COVID-19.
I am happy to share with you that Pfizer and our collaborator, BioNTech, announced positive efficacy results from our Phase 3, late-stage study of our potential COVID-19 vaccine. The vaccine candidate was found to be more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection in the first interim efficacy analysis.
The results demonstrate that our mRNA-based vaccine can help prevent COVID-19 in the majority of people who receive it. This means we are one step closer to potentially providing people around the world with a much-needed breakthrough to help bring an end to this global pandemic.
This is a first but critical step in our work to deliver a safe and effective vaccine.
It’s important to note that we cannot apply for FDA Emergency Use Authorization based on these efficacy results alone. More data on safety is also needed, and we are continuing to accumulate that safety data as part of our ongoing clinical study.
We estimate that a median of two months of safety data following the second and final dose of the vaccine candidate – required by FDA’s guidance for potential Emergency Use Authorization – will be available by the third week of November.
We are also generating data to show that our vaccine can be consistently manufactured to meet quality standards.
Efficacy, safety and consistent manufacturing are the three requirements that are needed before we are able to file for authorization.
We look forward to sharing additional updates in the coming weeks and will continue to work closely with regulatory authorities to provide access to our anticipated vaccine for those who need it most.
I want to thank the thousands of people who volunteered to participate in the clinical trial, our academic collaborators and investigators at the study sites, and our colleagues and collaborators around the world who are dedicating their time to this crucial endeavor.
We could not have come this far without the tremendous commitment of everyone involved. Their dedication and courage are the reasons we continue to believe that science will win.
Thank you all. –Albert Bourla Chief Executive Officer of Pfizer
Monday, November 09, 2020 – 06:45am
Vaccine candidate was found to be more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection in the first interim efficacy analysis
Analysis evaluated 94 confirmed cases of COVID-19 in trial participants
Study enrolled 43,538 participants, with 42% having diverse backgrounds, and no serious safety concerns have been observed; Safety and additional efficacy data continue to be collected
Submission for Emergency Use Authorization (EUA) to the U.S. Food and Drug Administration (FDA) planned for soon after the required safety milestone is achieved, which is currently expected to occur in the third week of November
Clinical trial to continue through to final analysis at 164 confirmed cases in order to collect further data and characterize the vaccine candidate’s performance against other study endpoints
NEW YORK & MAINZ, GERMANY–(BUSINESS WIRE)– Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced their mRNA-based vaccine candidate, BNT162b2, against SARS-CoV-2 has demonstrated evidence of efficacy against COVID-19 in participants without prior evidence of SARS-CoV-2 infection, based on the first interim efficacy analysis conducted on November 8, 2020 by an external, independent Data Monitoring Committee (DMC) from the Phase 3 clinical study.
“Today is a great day for science and humanity. The first set of results from our Phase 3 COVID-19 vaccine trial provides the initial evidence of our vaccine’s ability to prevent COVID-19,” said Dr. Albert Bourla, Pfizer Chairman and CEO. “We are reaching this critical milestone in our vaccine development program at a time when the world needs it most with infection rates setting new records, hospitals nearing over-capacity and economies struggling to reopen. With today’s news, we are a significant step closer to providing people around the world with a much-needed breakthrough to help bring an end to this global health crisis. We look forward to sharing additional efficacy and safety data generated from thousands of participants in the coming weeks.”After discussion with the FDA, the companies recently elected to drop the 32-case interim analysis and conduct the first interim analysis at a minimum of 62 cases. Upon the conclusion of those discussions, the evaluable case count reached 94 and the DMC performed its first analysis on all cases. The case split between vaccinated individuals and those who received the placebo indicates a vaccine efficacy rate above 90%, at 7 days after the second dose. This means that protection is achieved 28 days after the initiation of the vaccination, which consists of a 2-dose schedule. As the study continues, the final vaccine efficacy percentage may vary. The DMC has not reported any serious safety concerns and recommends that the study continue to collect additional safety and efficacy data as planned. The data will be discussed with regulatory authorities worldwide.
“I want to thank the thousands of people who volunteered to participate in the clinical trial, our academic collaborators and investigators at the study sites, and our colleagues and collaborators around the world who are dedicating their time to this crucial endeavor,” added Bourla. “We could not have come this far without the tremendous commitment of everyone involved.”
“The first interim analysis of our global Phase 3 study provides evidence that a vaccine may effectively prevent COVID-19. This is a victory for innovation, science and a global collaborative effort,” said Prof. Ugur Sahin, BioNTech co-founder and CEO. “When we embarked on this journey 10 months ago this is what we aspired to achieve. Especially today, while we are all in the midst of a second wave and many of us in lockdown, we appreciate even more how important this milestone is on our path towards ending this pandemic and for all of us to regain a sense of normality. We will continue to collect further data as the trial continues to enroll for a final analysis planned when a total of 164 confirmed COVID-19 cases have accrued. I would like to thank everyone who has contributed to make this important achievement possible.”
The Phase 3 clinical trial of BNT162b2 began on July 27 and has enrolled 43,538 participants to date, 38,955 of whom have received a second dose of the vaccine candidate as of November 8, 2020. Approximately 42% of global participants and 30% of U.S. participants have racially and ethnically diverse backgrounds. The trial is continuing to enroll and is expected to continue through the final analysis when a total of 164 confirmed COVID-19 cases have accrued. The study also will evaluate the potential for the vaccine candidate to provide protection against COVID-19 in those who have had prior exposure to SARS-CoV-2, as well as vaccine prevention against severe COVID-19 disease. In addition to the primary efficacy endpoints evaluating confirmed COVID-19 cases accruing from 7 days after the second dose, the final analysis now will include, with the approval of the FDA, new secondary endpoints evaluating efficacy based on cases accruing 14 days after the second dose as well. The companies believe that the addition of these secondary endpoints will help align data across all COVID-19 vaccine studies and allow for cross-trial learnings and comparisons between these novel vaccine platforms. The companies have posted an updated version of the study protocol at https://www.pfizer.com/science/coronavirus.
Pfizer and BioNTech are continuing to accumulate safety data and currently estimate that a median of two months of safety data following the second (and final) dose of the vaccine candidate – the amount of safety data specified by the FDA in its guidance for potential Emergency Use Authorization – will be available by the third week of November. Additionally, participants will continue to be monitored for long-term protection and safety for an additional two years after their second dose.
Along with the efficacy data generated from the clinical trial, Pfizer and BioNTech are working to prepare the necessary safety and manufacturing data to submit to the FDA to demonstrate the safety and quality of the vaccine product produced.
Based on current projections we expect to produce globally up to 50 million vaccine doses in 2020 and up to 1.3 billion doses in 2021.
Pfizer and BioNTech plan to submit data from the full Phase 3 trial for scientific peer-review publication.